Three-gene signature predicts disease progression of non-muscle invasive bladder cancer

Oncology Letters

Volumn 2, Issue 4, 2011, Pages 679-684

  Jeong, Pildu ^a   Ha, Yun Sok ^a   Cho, In Chang ^b   Yun, Seok Joong ^a   Yoo, Eun Sang ^c   Kim, Isaac Yi ^g   Choi, Yung Hyun ^d,e   Moon, Sung Kwon ^f   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Center for Prostate Cancer   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Dong Eui University   (South Korea)

^e Dong Eui University   (South Korea)

^f Chungju National University   (South Korea)

^g ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Bladder cancer; Cadherin EGF LAG seven pass G type receptor 3; Coagulation factor C homolog; Gene signature; Kinesin family member 1A; Prognosis; Quantitative real time PCR

Indexed keywords

CADHERIN; COMPLEMENTARY DNA; EGF LAG SEVEN PASS G TYPE RECEPTOR 3; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; KINESIN 1; LAMININ; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CHROMOSOME 2Q; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE SIGNATURE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTION; PROGNOSIS; PROTEIN FAMILY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79958068199     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.309     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin 58: 71-96, 2008.
2. Ha YS, Kim MJ, Yoon HY, Kang HW, Kim YJ, Yun SJ, Lee SC and Kim WJ: mRNA expression of S100A8 as a prognostic marker for progression of non-muscle-invasive bladder cancer. Korean J Urol 51: 15-20, 2010.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: S466-S477, 2006.
4. Borden LS Jr, Clark PE and Hall MC: Bladder cancer. Curr Opin Oncol 15: 227-233, 2003.
5. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ and Bae SC: Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 9: 3, 2010.
6. Shariat SF, Zippe C, Ludecke G, et al: Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173: 1518-1525, 2005.
7. Hong SJ, Cho KS, Han M, Rhew HY, Kim CS, Ryu SB, Sul CK, Chung MK, Park TC and Kim HJ: Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder. J Korean Med Sci 23: 428-433, 2008.
8. Habuchi T, Marberger M, Droller MJ, Hemstreet GP III, Grossman HB, Schalken JA, Schmitz-Drager BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y and Lokeshwar VB: Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66: 64-74, 2005.
9. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A and Palou-Redorta J: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54: 303-314, 2008.
10. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr and Schellhammer PF: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178: 2314-2330, 2007.
11. Greene FL: The american joint committee on cancer: updating the strategies in cancer staging. Bull Am Coll Surg 87: 13-15, 2002.
12. Bland JM and Altman DG: Transformations, means, and confidence intervals. BMJ 312: 1079, 1996.
13. Kim YJ, Ha YS, Kim SK, Yoon HY, Lym MS, Kim MJ, Moon SK, Choi YH and Kim WJ: Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 16: 2131-2137, 2010.
14. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ and Yang PC: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356: 11-20, 2007.
15. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D and Levy R: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350: 1828-1837, 2004.
16. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB and Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824, 2002.
17. Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, Massuti B, Chaib I, Perez-Roca L, Jassem J and Rosell R: Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 14: 4794-4799, 2008.
18. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J and Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
19. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O and Ogreid P: Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 169: 1291-1294, 2003.
20. Murphy WM, Takezawa K and Maruniak NA: Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol 168: 968-972, 2002.
21. Wu Q and Maniatis T: Large exons encoding multiple ectodomains are a characteristic feature of protocadherin genes. Proc Natl Acad Sci USA 97: 3124-3129, 2000.
22. Erkan M, Weis N, Pan Z, Schwager C, Samkharadze T, Jiang X, Wirkner U, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A and Kleeff J: Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer 9: 88, 2010.
23. Katoh M: WNT/PCP signaling pathway and human cancer (Review). Oncol Rep 14: 1583-1588, 2005.
24. Hirokawa N: Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 279: 519-526, 1998.
25. Aizawa H, Sekine Y, Takemura R, Zhang Z, Nangaku M and Hirokawa N: Kinesin family in murine central nervous system. J Cell Biol 119: 1287-1296, 1992.
26. Cui H, Dong M, Sadhu DN and Rosenberg DW: Suppression of kinesin expression disrupts adenomatous polyposis coli (APC) localization and affects beta-catenin turnover in young adult mouse colon (YAMC) epithelial cells. Exp Cell Res 280: 12-23, 2002.
27. Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, Argani P, Westra W, Van Criekinge W and Sidransky D: Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res 15: 1184-1191, 2009.
28. Uchiyama CM, Zhu J, Carroll RS, Leon SP and Black PM: Differential display of messenger ribonucleic acid: a useful technique for analyzing differential gene expression in human brain tumors. Neurosurgery 37 (Suppl): S464-S470, 1995.
29. Stearns ME and Wang M: Regulation of kinesin expression and type IV collagenase secretion in invasive human prostate PC-3 tumor sublines. Cancer Res 51: 5866-5875, 1991.
30. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, Grandis JR, Gaither Davis A, Bigbee WL, Rom W and Sidransky D: Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res 16: 3463-3472, 2010.
31. Tuckwell D: Evolution of von Willebrand factor A (VWA) domains. Biochem Soc Trans 27: 835-840, 1999.
32. Robertson NG, Skvorak AB, Yin Y, Weremowicz S, Johnson KR, Kovatch KA, Battey JF, Bieber FR and Morton CC: Mapping and characterization of a novel cochlear gene in human and in mouse: a positional candidate gene for a deafness disorder, DFNA9. Genomics 46: 345-354, 1997.
33. Rodriguez CI, Cheng JG, Liu L and Stewart CL: Cochlin, a secreted von Willebrand factor type a domain-containing factor, is regulated by leukemia inhibitory factor in the uterus at the time of embryo implantation. Endocrinology 145: 1410-1418, 2004.
34. Botteman MF, Pashos CL, Redaelli A, Laskin B and Hauser R: The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21: 1315-1330, 2003.
35. Divrik RT, Yildirim U, Zorlu F and Ozen H: The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 175: 1641-1644, 2006.
36. Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW and Studer UE: Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172: 70-75, 2004.
37. Ramani VA, Bromage SJ and Clarke NW: A contemporary standard for morbidity and outcome after radical cystectomy. BJU Int 104: 628-632, 2009.